Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | THPO | P40225 | 2/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.47 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.47 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9033536 | 0.83 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL9032893 | 0.83 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL10986834 | 0.82 | MAPT (0.50) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL30873727 | 0.81 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL20801670 | 0.81 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL3443986 | 0.79 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL9422622 | 0.79 | CYP1A2 (0.54) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL9422614 | 0.79 | CYP1A2 (0.54) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL7286552 | 0.79 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL7286542 | 0.79 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180098977-A1 | SCALABLE MICROPARTICULATE FORMULATIONS CONTAINING POLYMORPHIC NIMODIPINE FORM 2 PREPARED BY A SOLVENT EVAPORATION PROCESS | EDGE THERAPEUTICS, INC | 2018-04-12 | — | — | US | disclosed |
| US-9399019-B2 | Polymorph compositions, methods of making, and uses thereof | EVONIK CORPORATION (US) | 2016-07-26 | — | — | US | disclosed |
| EP-2846775-A2 | POLYMORPH COMPOSITIONS, METHODS OF MAKING, AND USES THEREOF | Evonik Corporation (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013169979-A9 | POLYMORPH COMPOSITIONS, METHODS OF MAKING, AND USES THEREOF | EDGE THERAPEUTICS, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| US-20140271895-A1 | Polymorph Compositions, Methods of Making, and Uses Thereof | EDGE THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8821944-B1 | Polymorph compositions, methods of making, and uses thereof | EVONIK CORPORATION | 2014-09-02 | — | — | US | disclosed |
| WO-2013169979-A2 | POLYMORPH COMPOSITIONS, METHODS OF MAKING, AND USES THEREOF | MACDONALD R LOCH (CA) | 2013-11-14 | — | — | WO | disclosed |
| US-20130302431-A1 | Polymorph Compositions, Methods of Making, and Uses Thereof | EVONIK CORPORATION | 2013-11-14 | — | — | US | disclosed |
| US-5519012-A | CALCIUM ANTAGONISTS, CARDIOVASCULAR DISORDERS | LEK, TOVARNA FARMACEVTSKIH IN KEMICNIH IZDELKOV, D.D., LJUBLJANA (SI) | 1996-05-21 | — | — | US | disclosed |
| EP-0566142-A1 | Inclusion complexes of optically active and racemic 1,4-dihydro pyridines with cyclodextrin derivates | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. (SI) | 1993-10-20 | — | — | EP | disclosed |
| EP-0555302-A1 | METHOD OF TREATING DEMYELINATING DISEASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-18 | — | — | EP | disclosed |
| WO-1992007564-A2 | METHOD OF TREATING DEMYELINATING DISEASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-14 | — | — | WO | disclosed |
| US-4504476-A | Method of administering calcium channel blocking agents | SCHWARTZ ARNOLD | 1985-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098977-A1 | SCALABLE MICROPARTICULATE FORMULATIONS CONTAINING POLYMORPHIC NIMODIPINE FORM 2 PREPARED BY A SOLVENT EVAPORATION PROCESS | CACNA1B, NIM1K, SLC6A4 | CYP1A2 470/4885CYP3A4 183/4885CYP2C9 550/4885 |
| US-20140271895-A1 | Polymorph Compositions, Methods of Making, and Uses Thereof | PGF, BDNF, PYGB | CYP1A2 1222/4885CYP3A4 552/4885CYP2C9 1360/4885 |
| US-20130302431-A1 | Polymorph Compositions, Methods of Making, and Uses Thereof | PGF, BDNF, PYGB | CYP1A2 1222/4885CYP3A4 552/4885CYP2C9 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.